← All candidates
50 insider filings on record.
50 filings on record.
CLPTClearPoint Neuro, Inc.
NasdaqCM · Healthcare · $408.76M
$13.40
+1.90% today
50 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 11 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CLPT ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$408.76M
Float
26.3M
86% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
9.7
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
45 more transactions on Pro →Context
Wall St
$28.33 avg target
+111.4% vs today · 3 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q1 '26−$0.32 act−$0.05
Q4 '25−$0.27 act−$0.07
Q3 '25−$0.21 act−$0.01
Q2 '25−$0.21 act−$0.01
Coverage
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?Zacks · 06-18ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform ValueInvestorsHub · 06-17How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA RisksSimply Wall St. · 05-27ClearPoint Neuro Inc (CLPT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic GrowthGuruFocus.com · 05-19
The file stays open
50 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice